{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:42:38Z","timestamp":1792572158756,"version":"4.5.0"},"reference-count":35,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100007161","name":"Boston University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001797","name":"Pharmaceutical Research and Manufacturers of America Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 CA273645"],"award-info":[{"award-number":["R21 CA273645"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody drug conjugates (ADCs) are a key therapy in the cancer treatment arsenal. Critical to the success of the ADC is the release of the drug cargo at the desired site, and thus, enzymatically or chemically responsive linkers, connecting the drug to the antibody, play a central role. Linkers containing the peptide sequence Glu-Val-Cit are particularly important as cleavage of this peptide occurs by both murine and human cathepsin B enzymes. Additional linker design considerations include components for free drug release via the self-immolative moiety para-aminobenzyl alcohol (PABOH), copper-free click conjugation to an azide-functionalized antibody using dibenzocyclooctyne (DBCO), and aqueous solubility via a polyethylene glycol spacer (PEG). To facilitate widespread use and translation, we describe the 9-step gram-scale synthesis of the linker DBCO-PEG4-Glu-Val-Cit-PABOH conjugated to monomethyl auristatin E (MMAE). Using only liquid-phase synthesis protocols and chromatography-free, precipitation-based intermediate isolations gives the drug-linker conjugate in 36% overall yield, and this method is an improvement over prior methods (yield &amp;lt; 1%). Finally, we prepare the corresponding MMAE-linked ADC and validate its target-dependent potency across ErbB2\/Her2-high (MDA-MB-453) and ErbB2\/Her2-low (MDA-MB-231) human breast cancer cell lines.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00437","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:02:15Z","timestamp":1791543735000},"page":"2092-2100","source":"Crossref","is-referenced-by-count":0,"title":["Facile Gram-Scale Solution Phase Synthesis of a Universal Cathepsin B-Cleavable Antibody-Drug Conjugate Linker"],"prefix":"10.1021","volume":"37","author":[{"given":"Alina","family":"Ringaci","sequence":"first","affiliation":[{"name":"Boston University , , , ,","place":["Boston, Massachusetts, United States, 02215"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aladin","family":"Hamoud","sequence":"additional","affiliation":[{"name":"Boston University , , , ,","place":["Boston, Massachusetts, United States, 02215"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolonda L.","family":"Colson","sequence":"additional","affiliation":[{"name":"Massachusetts General Brigham, Harvard Medical School , , , ,","place":["Boston, Massachusetts, United States, 02115"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5453-3668","authenticated-orcid":true,"given":"Mark W.","family":"Grinstaff","sequence":"additional","affiliation":[{"name":"Boston University , , , ,","place":["Boston, Massachusetts, United States, 02215"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"2026102103085127100_cit1","doi-asserted-by":"publisher","first-page":"114408","DOI":"10.1016\/j.biopha.2023.114408","article-title":"A Comprehensive Review of Key Factors Affecting the Efficacy of Antibody Drug Conjugate","volume":"161","author":"Samantasinghar","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"2026102103085127100_cit2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2212Drug Conjugates Come of Age in Oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"7","key":"2026102103085127100_cit3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-021-00484-2","article-title":"The Clinical Development of Antibody\u2212Drug Conjugates \ue5f8 Lessons from Leukaemia","volume":"18","author":"Jabbour","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"2026102103085127100_cit4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-Drug Conjugates in Lung Cancer: Dawn of a New Era?","volume":"7","author":"Coleman","year":"2023","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"2026102103085127100_cit5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody \u2212 Drug Conjugates in Cancer Therapy: Current Landscape, Challenges, and Future Directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"2026102103085127100_cit6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody Drug Conjugate: The \u201cBiological Missile\u201d for Targeted Cancer Therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduction Targeted Ther."},{"key":"2026102103085127100_cit7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the Potential of Antibody\u2212Drug Conjugates for Cancer Therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"2026102103085127100_cit8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of Therapeutic Antibodies for the Treatment of Diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"2026102103085127100_cit9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging New Therapeutic Antibody Derivatives for Cancer Treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduction Targeted Ther."},{"issue":"9","key":"2026102103085127100_cit10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.2021015246","article-title":"Targeting FLT3 with a New-Generation Antibody-Drug Conjugate in Combination with Kinase Inhibitors for Treatment of AML","volume":"141","author":"Roas","year":"2023","journal-title":"Blood"},{"key":"2026102103085127100_cit11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and Challenges for the next Generation of Antibody\u2212Drug Conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug. Discov."},{"key":"2026102103085127100_cit12","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody \u2212 Drug Conjugates : Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"10200","key":"2026102103085127100_cit13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2212Drug Conjugates for Cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"issue":"15","key":"2026102103085127100_cit14","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500262","article-title":"Linker Design for the Antibody Drug Conjugates: A Comprehensive Review","volume":"20","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"issue":"12","key":"2026102103085127100_cit15","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody Drug Conjugates and Bystander Killing: Is Antigen-Dependent Internalisation Required","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"2","key":"2026102103085127100_cit16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1021\/acs.bioconjchem.7b00576","article-title":"Immolation of P-Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibody-Drug Conjugates with Phenol-Containing Payloads","volume":"29","author":"Zhang","year":"2018","journal-title":"Bioconjugate Chem."},{"issue":"40","key":"2026102103085127100_cit17","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1016\/j.tetlet.2018.08.021","article-title":"Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research","volume":"59","author":"Mondal","year":"2018","journal-title":"Tetrahedron Lett."},{"issue":"10","key":"2026102103085127100_cit18","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1021\/bc800289a","article-title":"Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate","volume":"19","author":"Doronina","year":"2008","journal-title":"Bioconjugate Chem."},{"issue":"5","key":"2026102103085127100_cit19","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/1535-7163.MCT-15-1004","article-title":"Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design","volume":"15","author":"Dorywalska","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"2026102103085127100_cit20","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/s41467-018-04982-3","article-title":"Glutamic Acid-Valine-Citrulline Linkers Ensure Stability and Efficacy of Antibody-Drug Conjugates in Mice","volume":"9","author":"Anami","year":"2018","journal-title":"Nat. Commun."},{"key":"2026102103085127100_cit21","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1021\/acs.bioconjchem.0c00563","article-title":"Rapid, High-Yielding Solid-Phase Synthesis of Cathepsin-BCleavable Linkers for Targeted Cancer Therapeutics","volume":"31","author":"Pryyma","year":"2020","journal-title":"Bioconjugate Chem."},{"issue":"8","key":"2026102103085127100_cit22","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1021\/acs.joc.8b03001","article-title":"Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production","volume":"84","author":"Isidro-Llobet","year":"2019","journal-title":"J. Org. Chem."},{"issue":"1","key":"2026102103085127100_cit23","doi-asserted-by":"publisher","DOI":"10.1002\/cpps.97","article-title":"Gram-Scale Preparation of C-Terminal-Modified Enkephalin Analogues by Typical Liquid-Phase Peptide Synthesis","volume":"98","author":"Lee","year":"2019","journal-title":"Curr. Protoc. Protein Sci."},{"issue":"10","key":"2026102103085127100_cit24","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1007\/s11095-008-9616-1","article-title":"Click Chemistry, a Powerful Tool for Pharmaceutical Sciences","volume":"25","author":"Hein","year":"2008","journal-title":"Pharm. Res."},{"issue":"34","key":"2026102103085127100_cit25","doi-asserted-by":"publisher","first-page":"7835","DOI":"10.1039\/c9sc03368h","article-title":"Biomedical Applications of Copper-Free Click Chemistry: In Vitro, in Vivo, and Ex Vivo","volume":"10","author":"Kim","year":"2019","journal-title":"Chem. Sci."},{"issue":"8","key":"2026102103085127100_cit26","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1021\/acs.oprd.2c00227","article-title":"Payloads for Antibody-Drug Conjugates","volume":"26","author":"Goundry","year":"2022","journal-title":"Org. Process Res. Dev."},{"issue":"10","key":"2026102103085127100_cit27","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2212Drug Conjugates: Recent Advances in Payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"2026102103085127100_cit28","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1021\/acs.bioconjchem.7b00304","article-title":"Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates","volume":"28","author":"Dal Corso","year":"2017","journal-title":"Bioconjugate Chem."},{"issue":"3","key":"2026102103085127100_cit29","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3390\/cancers12030744","article-title":"Antibody-Drug Conjugate Using Ionized CYS-Linker-Mmae as the Potent Payload Shows Optimal Therapeutic Safety","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers"},{"issue":"9","key":"2026102103085127100_cit30","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.62347\/FOWU3488","article-title":"Therapeutic Challenges in HER2-Targeted Antibody Therapies : Trastuzumab and Its ADC Derivatives in Breast Cancer","volume":"15","author":"Lin","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"5","key":"2026102103085127100_cit31","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-020-05094-1","article-title":"HER2-Directed Antibodies, Affibodies and Nanobodies as Drug-Delivery Vehicles in Breast Cancer with a Specific Focus on Radioimmunotherapy and Radioimmunoimaging","volume":"48","author":"Altunay","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"19","key":"2026102103085127100_cit32","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/0008-5472.CAN-13-3622-T","article-title":"Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells","volume":"74","author":"Junttila","year":"2014","journal-title":"Cancer Res."},{"issue":"9","key":"2026102103085127100_cit33","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1039\/c9bm01764j","article-title":"Trastuzumab Targeted Micellar Delivery of Docetaxel Using Dendron \u2212 Polymer Conjugates","volume":"8","author":"Sumer Bolu","year":"2020","journal-title":"Biomater. Sci."},{"key":"2026102103085127100_cit34","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/jcp.27085","article-title":"Trastuzumab-Monomethyl Auristatin E Conjugate Exhibits Potent Cytotoxic Activity in Vitro against HER2 - Positive Human Breast Cancer","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"2026102103085127100_cit35","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.7150\/thno.51232","article-title":"A Bifunctional Molecule-Based Strategy for the Development of Theranostic Antibody-Drug Conjugate","volume":"11","author":"Xiao","year":"2021","journal-title":"Theranostics"}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00437","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/2092\/68797022\/bc6c00437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/2092\/68797022\/bc6c00437.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:11:00Z","timestamp":1792570260000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/10\/2092\/5447612\/Facile-Gram-Scale-Solution-Phase-Synthesis-of-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,9]]},"published-print":{"date-parts":[[2026,10,21]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00437","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv.15002651\/v1","asserted-by":"object"}]},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]}}}